The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by hallucinogenic drugs.
T Yamamoto, S Ueki
Pharmacology, Biochemistry, and Behavior January 1981 DOI: 10.1016/0091-3057(81)90108-8 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal experimental study Peer reviewed |
|---|---|
| Population | Rodents (species not stated) |
| Interventions | Lysergic acid diethylamide Mescaline 2 5-dimethoxy-4-methylamphetamine (DOM) Methysergide PCPA medial raphe lesions |
| Topics | Serotonin |
| Key findings | Medial raphe lesions increased hallucinogen-induced head twitch, while dorsal raphe lesions had no effect, suggesting 5-HT receptors innervated by the ascending medial raphe pathway are involved in this behavior, with the increase attributed to receptor supersensitivity. DOM-induced backward locomotion was inhibited by medial raphe or combined raphe lesions and methysergide and reversed to forward locomotion, a pattern distinct from head twitch. |
Abstract
Head-twitch induced by lysergic acid diethylamide, mescaline and 2,5-dimethoxy-4-methylamphetamine (DOM) was significantly increased by medial raphe (m-R) lesions, but dorsal raphe (d-R) lesions did not produce any changes. Hallucinogen-induced head twitch was inhibited by methysergide and tended to be increased by PCPA. These results suggest that 5-HT receptors innervated with the ascending 5-HT pathway originating in the m-R play a vital role in the manifestation of hallucinogen-induced head-twitch. That is, increase of head-twitch is ascribed to supersensitivity of 5-HT receptors. On the other hand, DOM-induced backward locomotion was inhibited by m-R or both dorsal and medial raphe lesions and methysergide, and was reversed to forward locomotion, differently from the hallucinogen-induced head-twitch. A reversion of backward locomotion was not obtained with d-R lesions or PCPA treatment.
Comparable studies
Other preclinical and animal studies on serotonin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo Mice | 2021 | Observational cohort | |
| Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Rats (implied by typical neurochemical study context) | 1987 | Experimental study | |
| Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors In vitro and in vivo (rodent) models | 2023 | Experimental study | |
| 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Rat brain | 1987 | Animal experiment | |
| Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs Human and mouse dopamine, norepinephrine, and serotonin transporters expressed in cells | 2006 | In vitro laboratory study |
Citations in the library
Cited by 14
- Animal Models of Serotonergic Psychedelics ACS Chemical Neuroscience September 24, 2012
- Mescaline‐induced head‐twitches in the rat: An in vivo method to evaluate serotonin S2 antagonists Drug Development Research 1983
- Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia. Naunyn-Schmiedeberg's Archives of Pharmacology June 1, 1990
- Phencyclidine-induced head-twitch response in rats treated chronically with methysergide. European Journal of Pharmacology January 20, 1987
- Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) Pharmacology, Biochemistry, and Behavior December 15, 2011
and 9 more in the library